Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Drug Interaction of Minoxidil and Himplasia with Oral Anti Diabetic Drug Sitagliptin in Diabetic Rats


Affiliations
1 Senior Research Scientist, Radiant Research Services Pvt Ltd., Bangalore, Karnataka - 560058., India
2 Head Technical Operatations, Radiant Research Services Pvt Ltd., Bangalore, Karnataka - 560058., India
3 Department of Pharmacology, T. John College of Pharmacy, Bangalore, Karnataka – 560083., India
4 Department of Pharmacology, PGP College of Pharmaceutical Sciences and Research Institute, Namakkal, Tamil Nadu – 637207., India
     

   Subscribe/Renew Journal


Aim and Objective: Sitagliptin is given as an oral antidiabetic drug to treat Diabetes Mellitus. Minoxidil and himplasia may be co-prescribed along with sitagliptin to treat hypertension and BPH respectively. As such no information is available regarding the interaction taking place between sitagliptin, minoxidil and himplasia. Hence the present work has been aimed to find out the interaction with among the above said drugs in rodent model, since such studies cannot be performed in humans. Methods: Studies were conducted in normal and alloxan induced diabetic rats with oral doses of 9mg/kg B.W of sitagliptin, 9mg/kg B.W of minoxidil and 54mg /k g of himplasia and their combinations with adequate washout periods in between the treatments. Blood samples were collected at regular time intervals in rats throughretro orbital puncture. All the blood samples were analyzed for blood glucose by GOD/POD method in pharmacodynamic studies and the serum sitagliptin concentrations were estimated by UV Spectrophotometry. Serum insulin was estimated by chemiluminescence assay. Results: Sitagliptin showed hypoglycemic action in both normal and diabetic rats and the peak action was observed at 6 h. Hyperglycemia was observed with minoxidil at 1st hour, hypoglycemia was observed with himplasia at 4th hour and the combination of minoxidiland himplasia showed biphasic response in blood glucose levels. The same responses were observed even in combination with sitagliptin. The serum sitagliptin concentrations were not altered by the co-administration of drugs. Serum insulin levels were inhibited by administration of minoxidil and potentiated by himplasia and initial reduction followed by surge observed with combination of minoxidil and himplasia. The similar responses were observed when co-administered with sitagliptin. Conclusion: Thus it could be concluded that the combination of minoxidil and himplasia should be taken with care for clinical benefits in diabetic patients. However, further studies should be carried out in non rodent species and in clinical settings are warranted.

Keywords

Diabetes mellitus, Sitagliptin, Minoxidil, Himplasia, Drug interactions, Chemiluminescence assay.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Nwauche Kelechi T, Monago Comfort C, Onwuka Franscis.Management of Diabetic with Combined Therapy of Reducdyn and Metformin in Streptozotocin induced Diabetic Male Rats. Research J. Pharmacognosy and Phytochemistry 2013; 5(5):224-235.

  • Mamatha M K, Suma US, Annegowda HV. The Ascent of Polyherbal Formulation in the Treatment of Diabetes Mellitus. Res. J. Pharmacognosy and Phytochem. 2020; 12(4):256-260.

  • SM Bhanushali, KM Modh, IS Anand, CN Patel, JB Dave. Novel Approaches for Diabetes Mellitus: A Review. Research J. Pharmacology and Pharmacodynamics. 2010; 2(2):141-147.

  • Hazaratali Panari, Vegunarani. M. Study on Complications of Diabetes Mellitus among the Diabetic Patients. Asian J. Nur. Edu. and Research. 2016; 6(2): 171-182.

  • Cerveny JD, Leder RD and Weart CW. Issues surrounding tight glycaemic control in people with type 2 diabetes mellitus. Annpharmacother 1998;32(9):869-905.

  • Aaron Vinik and Mark Flemmern. Diabetes and macrovascular disease. Journal of Diabetes and Its Complications. 2002; 16: 235– 45.

  • Shom Prakash Kushwaha, Sunil Kumar Rawat, Pavan Kumar, Abhishek, Kishu Tripathi. Coupling Antioxidant and Antidiabetic assets of 2, 4-Thiazolidinedione Derivatives. Asian J. Pharm. Ana. 1(4): Oct. - Dec. 2011; Page 71-73.

  • Mitchell JR, Arias L and Oates JA. Antagonism of the antihypertensive actions og guanethidine sulphate by desipramine hydrochloride. J Am Med Ass 1967; 202:973.

  • Leishmann AWD, Mathews HL and Smith AJ. Antagonism of guanethidine by imipramine. Lancet 1963; 1:112.

  • Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. 11th ed 2006:862-63.

  • J.Girard. The Incretins: From the concept to their use in treatment of type 2 diabetes. Part A: Incretins: Concept and Physiological functions. Diabetes and Metabolism 2008; 34: 550-59.

  • Laurence DR, Bacharach AL. Evaluation of drug activities and pharmacometrics. London and New York: Academic Press ;1964.

  • Manjula K.Pandit, John Burke, Antony B. Gustafson, Anil Minocha, Alan N. Peiris. Drug Induced Disorders of Glucose Tolerance.1993;118(7):529-39.

  • WHO Expert Committee on Diabetes Mellitus. Second Report. Geneva: WHO, 1980. Technical Report Series 646.

  • Sathish Kumar Konidala, Pampana V V Suresh Babu , Ranj, K S D Ranjitha. RP-HPLC Method Development and Validation for the Simultaneous Estimation of Sitagliptin and Simvastatin in Pharmaceutical Formulation. Asian J. Pharm. Ana. 2016; 6(2): 68- 76.

  • P. Jaya Preethi. Herbal Medicine for Diabetes Mellitus: A Review. Asian J. Pharm. Res. 3(2): April- June 2013; Page 57-70

  • Lederballe Pedersen O. Long- term experiences with minoxidil in combination treatment of severe arterial hypertension. Acta Cardiol. 1997; 32:283-93.

  • Brunchwaig A, Allen JG, Goldner MG, Gomori G. Alloxan. J Am Med Ass 1943; 122:966.

  • Rakienten N, Rakienten ML, Nadakarni MV. Studies on the diabetogenic action of streptozocin. Cancer Chemother Rep 1963;29: 91-92.

  • SM Bhanushali, KM Modh, IS Anand, CN Patel , JB Dave. Novel Approaches for Diabetes Mellitus: A Review. Research J. Pharmacology and Pharmacodynamics. 2010; 2(2):141-147.

  • Nagesh HS, Saraswathi CD, Uday Mohan Reddy P, Archana Swamy P, Varshitha C. Antidiabetic Activities of Euphorbia Nivulia Buch in Alloxan Induced Diabetic Rats. Research Journal of Pharmacology and Pharmacodynamics. 2014; 6(1): 8-12.

  • I Srivallika, P Shivasri, M Ramesh, P Jony Basha, T Vinay Kumar, B Ram Sarath Kumar, D Rajesh Kumar. Evaluation of AntiHyperglycaemic Activity of Polyherbal Formulation by using InVitro Methods. Research Journal of Pharmacology and Pharmacodynamics. 2014; 6(1): 36-40.


Abstract Views: 241

PDF Views: 0




  • Drug Interaction of Minoxidil and Himplasia with Oral Anti Diabetic Drug Sitagliptin in Diabetic Rats

Abstract Views: 241  |  PDF Views: 0

Authors

Dhanapuram Akhila Banu
Senior Research Scientist, Radiant Research Services Pvt Ltd., Bangalore, Karnataka - 560058., India
Gopi Mareedu
Head Technical Operatations, Radiant Research Services Pvt Ltd., Bangalore, Karnataka - 560058., India
Vivek B
Department of Pharmacology, T. John College of Pharmacy, Bangalore, Karnataka – 560083., India
Velmurugan C
Department of Pharmacology, PGP College of Pharmaceutical Sciences and Research Institute, Namakkal, Tamil Nadu – 637207., India

Abstract


Aim and Objective: Sitagliptin is given as an oral antidiabetic drug to treat Diabetes Mellitus. Minoxidil and himplasia may be co-prescribed along with sitagliptin to treat hypertension and BPH respectively. As such no information is available regarding the interaction taking place between sitagliptin, minoxidil and himplasia. Hence the present work has been aimed to find out the interaction with among the above said drugs in rodent model, since such studies cannot be performed in humans. Methods: Studies were conducted in normal and alloxan induced diabetic rats with oral doses of 9mg/kg B.W of sitagliptin, 9mg/kg B.W of minoxidil and 54mg /k g of himplasia and their combinations with adequate washout periods in between the treatments. Blood samples were collected at regular time intervals in rats throughretro orbital puncture. All the blood samples were analyzed for blood glucose by GOD/POD method in pharmacodynamic studies and the serum sitagliptin concentrations were estimated by UV Spectrophotometry. Serum insulin was estimated by chemiluminescence assay. Results: Sitagliptin showed hypoglycemic action in both normal and diabetic rats and the peak action was observed at 6 h. Hyperglycemia was observed with minoxidil at 1st hour, hypoglycemia was observed with himplasia at 4th hour and the combination of minoxidiland himplasia showed biphasic response in blood glucose levels. The same responses were observed even in combination with sitagliptin. The serum sitagliptin concentrations were not altered by the co-administration of drugs. Serum insulin levels were inhibited by administration of minoxidil and potentiated by himplasia and initial reduction followed by surge observed with combination of minoxidil and himplasia. The similar responses were observed when co-administered with sitagliptin. Conclusion: Thus it could be concluded that the combination of minoxidil and himplasia should be taken with care for clinical benefits in diabetic patients. However, further studies should be carried out in non rodent species and in clinical settings are warranted.

Keywords


Diabetes mellitus, Sitagliptin, Minoxidil, Himplasia, Drug interactions, Chemiluminescence assay.

References